ALIM News Alert Alimera Sciences (ALIM) 5.43 12/25/2014 09:3

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Alimera Sciences (ALIM) 5.43 $ALIM

Alimera Sciences Added to NASDAQ Biotechnology Index
PR Newswire - Tue Dec 16, 7:30AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it has been added to the NASDAQ Biotechnology Index (NASDAQ:NBI). The addition to the NASDAQ Biotechnology Index will become effective upon market open on December 22, 2014.
ALIM: 5.43 (-0.06)

Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST

TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

Alimera Sciences Announces Closing of $50.0 Million Financing with Deerfield Management
PR Newswire - Mon Dec 15, 7:45AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it has closed its offering of Series B Preferred Stock with Deerfield Management and certain of its affiliates (Deerfield). Alimera issued Deerfield an aggregate of 8,291.873 shares of Series B Preferred Stock for a purchase price of $6,030.00 per share, or an aggregate purchase price of approximately $50.0 million. Each share of Series B Preferred Stock is convertible into 1,000 shares of Alimera's common stock at any time at the option of the holder, provided that the holder is prohibited from converting Series B Preferred Stock into shares of Alimera's common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.98% of the total number of shares of Alimera's common stock then issued and outstanding. Alimera also issued an additional 124.378 shares of Series B Preferred Stock to Deerfield as a subscription premium. The Series B Preferred Stock is not redeemable at the option of the holder. The Series B Preferred Stock is not subject to any price-based or other anti-dilution protections and does not provide for any accruing dividends. Except as otherwise required by law (or with respect to approval of certain actions), the Series B Preferred Stock does not have voting rights. Alimera plans to use the proceeds for commercial launch of its lead product, ILUVIEN, in the United States, continued marketing efforts in Europe and general corporate purposes.
ALIM: 5.43 (-0.06)

Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

Insider Trading Alert - OUTR, ALIM And CINF Traded By Insiders
at The Street - Wed Dec 03, 12:00PM CST
Stocks with insider trader activity include OUTR, ALIM and CINF
CINF: 52.18 (-0.19), ALIM: 5.43 (-0.06), OUTR: 72.88 (-2.00)

Iluvien cleared in the Netherlands
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 2:28PM CST

ALIM: 5.43 (-0.06), PSDV: 4.00 (-0.03)

Alimera Sciences' ILUVIEN® Receives Marketing Authorization In The Netherlands For The Treatment Of Chronic Diabetic Macular Edema
PR Newswire - Mon Dec 01, 2:00PM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Dutch Inspectie voor de Gezondheidszorg (IGZ) has granted marketing authorization in the Netherlands to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
ALIM: 5.43 (-0.06)

Alimera secures new financing
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:57AM CST

ALIM: 5.43 (-0.06)

Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing
PR Newswire - Fri Nov 28, 7:30AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, has entered into a Securities Purchase Agreement with Deerfield Management and certain of its affiliates ("Deerfield" pursuant to which Alimera will issue shares of preferred stock to Deerfield with an aggregate purchase price of approximately $50.0 million upon the satisfaction of certain closing conditions. Alimera has also agreed to issue an additional 124.378 shares of preferred stock as a subscription premium. The preferred stock will be convertible into an aggregate of 8,416,251 shares of Alimera common stock. Alimera plans to use the proceeds for commercial launch of its lead product, ILUVIEN, in the United States, continued marketing efforts in Europe and general corporate purposes.
ALIM: 5.43 (-0.06)

Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Ireland For The Treatment Of Chronic Diabetic Macular Edema
PR Newswire - Mon Nov 17, 10:45AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Irish Health Products Regulatory Authority (HPRA) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
ALIM: 5.43 (-0.06)

Alimera Sciences wins marketing authorisation in Belgium for ILUVIEN for chronic diabetic macular edema
M2 - Thu Nov 13, 7:08AM CST
Pharmaceutical company Alimera Sciences (NasdaqGM:ALIM) reported on Thursday the receipt of the Belgian Federal Agency for Medicines and Health Products' (FAMHP) marketing approval for ILUVIEN for treating vision impairment with chronic diabetic macular edema (DME) insufficiently responsive to available therapies.
ALIM: 5.43 (-0.06)

Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Belgium For The Treatment Of Chronic Diabetic Macular Edema
PR Newswire - Wed Nov 12, 6:30AM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Belgian Federal Agency for Medicines and Health Products (FAMHP) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
ALIM: 5.43 (-0.06)

Alimera Sciences' (ALIM) CEO Daniel Myers on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 10:46PM CST

ALIM: 5.43 (-0.06)

Alimera Sciences beats by $0.48, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:19PM CST

ALIM: 5.43 (-0.06)

Alimera Sciences (ALIM) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 3:25PM CST

ALIM: 5.43 (-0.06)

Alimera Sciences Reports Third Quarter 2014 Financial Results
PR Newswire - Thu Nov 06, 3:13PM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the third quarter ended September 30, 2014.
ALIM: 5.43 (-0.06)

Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:35PM CST

BEBE: 2.48 (-0.15), ACET: 21.85 (-0.07), ANET: 65.00 (+0.30), FNGN: 37.85 (+0.79), CPST: 0.74 (+0.01), AUQ: 3.08 (+0.10), AMRN: 0.99 (unch), ED: 66.91 (+0.90), ENV: 51.94 (+1.62), FXCM: 16.88 (-0.12), BCEI: 23.25 (-0.62), GXP: 28.09 (+0.35), EAC: 8.13 (+0.02), DXCM: 54.94 (+0.99), CSC: 64.36 (+0.24), AEL: 28.73 (+0.12), HNSN: 0.55 (-0.02), CFN: 59.18 (+0.04), ANAC: 30.58 (+0.16), DAR: 18.35 (-0.06), GST: 2.47 (-0.03), ARC: 9.80 (+0.12), FIVN: 4.56 (+0.11), ELON: 1.72 (+0.03), FSLR: 43.67 (-0.39), EZPW: 11.48 (-0.20), ALIM: 5.43 (-0.06), FWM: 2.80 (-0.03), BRS: 64.93 (+0.02), ECOM: 21.95 (+0.19), FTEK: 3.73 (+0.03), CVT: 27.66 (+0.26), AL: 34.20 (+0.12), BBRG: 12.66 (-0.18), BPZ: 0.25 (+0.03), ECPG: 43.81 (-0.11), HTGC: 15.13 (+0.39), AIRM: 43.03 (-0.10), BNFT: 32.78 (+0.75), ENOC: 15.37 (+0.03), HPTX: 21.91 (-0.08), AGO: 26.28 (+0.23), FICO: 72.85 (+0.40), FF: 13.09 (+0.23), FI: 16.80 (-0.22), EVC: 6.59 (+0.09), EBS: 27.64 (+1.28), ABCO: 49.30 (-0.58), DIOD: 27.55 (+0.29), DIS: 94.42 (-0.27), EGOV: 18.66 (+0.19), APEI: 36.33 (+0.24), DVA: 76.06 (+0.07), CLVS: 54.58 (+0.43), HCI: 45.48 (-0.09), BRKR: 19.50 (+0.09), HGR: 23.20 (+0.12)

Nasdaq stocks posting largest percentage decreases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
BRDR: 8.52 (+0.05), ALIM: 5.43 (-0.06), ACHN: 13.06 (+1.22), FNHC: 25.30 (+0.45), ARCP: 8.33 (unch), CKEC: 26.09 (+0.10), JAXB: 12.26 (+0.96), PCLN: 1,149.78 (+2.17), TESO: 12.71 (-0.42)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 108

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor

Updated Category News Views 95

Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 138

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 147

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
Epiroc Takes Live Remote Drilling to CES 2027 Stage

Updated Category News Views 48

A drill rig chewing through Virginia rock from a Las Vegas convention booth is either a serious industrial-tech moment or an expensive magic trick. At CES 2027, Epiroc intends to make the distinction painfully clear. From January 6 through 9, the Stockholm-based mining-equipment company and Luck Stone will connect Booth 7031 in the LVCC West Hall to a working quarry in...

Continue Reading
Lara Kirchner's Surgical Leadership Earns Recognition

Updated Category News Views 64

Surgical care gets judged in the quiet moments nobody puts on a plaque: a sterile instrument ready when it must be, a handoff done cleanly, a team that does not let a rushed schedule turn into a bad outcome. That is why Lara L. Kirchner's recognition as a Pinnacle Professional of the Year deserves a more serious look than the usual congratulatory confetti. Kirchner is...

Continue Reading
CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 76

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
West Virginia SEO Timelines Demand Patience, Not Hype

Updated Category News Views 99

A fresh website with no search footprint is not a race car; it is a pickup stuck in mud, and Sean O'Kelly's view of local SEO in West Virginia puts that inconvenient fact right on the table. Most businesses can expect measurable improvement after three to six months of consistent work, according to the HelloNation article. That is not a glamorous answer, but it is the...

Continue Reading
Triller Lawsuit Puts Merger Disclosures Under a Harsh Light

Updated Category News Views 90

A $0.32 closing price has a way of stripping the paint off a corporate story. The proposed securities class action involving Triller Group, Inc. puts a hard spotlight on a familiar, ugly market sequence: a splashy merger, glowing talk around acquired assets, delayed financial filings, Nasdaq trouble, and then a collapse severe enough to leave shareholders wondering what...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 27

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading

Top 5 Most Recently Viewed Articles

Director Declaration - Northern 2 VCT PLC

Updated Category News Views 143

Director Declaration - Northern 2 VCT PLC Northern 2 VCT PLC (“the Company”) has announced that Ranjan Ramparia, who currently serves as a non-executive director and audit Chair of the Company, will take on a new role as a non-executive director at Keystone Positive Change Investment Trust plc. Disclosure Compliance In line with the UK Listing Rules, there are no...

Continue Reading
Exploring WisdomTree's Diverse Fund Offerings and Prices

Updated Category News Views 119

Understanding WisdomTree's Daily Fund Prices WisdomTree Issuer plc, renowned for its innovative investment strategies, provides a range of ETF products that cater to various investment needs. The company focuses on not just traditional asset classes but also on megatrends shaping the future. Investors looking to stay updated on their financial assets can explore the daily...

Continue Reading
Atlantic American Corporation Sees Positive Growth in Q1 Results

Updated Category News Views 198

Atlantic American Corporation Achieves Strong Q1 Performance Atlantic American Corporation (NASDAQ: AAME) recently announced its financial results for the first quarter of the year, showcasing a significant turnaround in performance. The company reported a net income of $0.8 million, translating to $0.03 per diluted share. This marks a remarkable recovery from a net loss...

Continue Reading
CTT's Growth in Q3 2024: A Promising Outlook for Q4

Updated Category News Views 80

CTT's Impressive Q3 Performance CTT (CTT.LS) reported a stellar third quarter, showcasing significant revenue growth and a bright outlook for the fourth quarter. As discussed by CEO Joao Bento, the company achieved a remarkable 17.3% increase in revenue, accompanied by a 28.6% rise in EBIT when excluding Financial Services. This transition period highlights CTT's...

Continue Reading
Global Leaders Unite for Climate Justice Summit in NYC

Updated Category News Views 186

Global Leaders Come Together for Climate Justice Summit in NYC The Climate Justice Summit: People Deliver marks a significant kickoff for Climate Week in New York City. This vibrant event will gather a broad spectrum of climate justice advocates from around the world, who will collaborate and share their insights. A coalition of key organizations, including the HBCU Green...

Continue Reading